

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Gaush Meditech Ltd**

**高视医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2407)**

## **VOLUNTARY ANNOUNCEMENT ANTERION OBTAINED NMPA MEDICAL DEVICE REGISTRATION CERTIFICATE**

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, ANTERION (three-in-one anterior segment multimodal imaging diagnostic platform) launched by Heiderberg Engineering GmbH (“**HEIDERBERG**”), an important upstream partner represented by Global Vision Corporation\* (北京高視遠望科技有限責任公司), a wholly-owned subsidiary of the Company, recently obtained the medical device registration certificate approved by the National Medical Products Administration (NMPA) of the People’s Republic of China.

ANTERION is a multimodal imaging diagnostic platform that integrates biometer, corneal topography and anterior segment OCT. It can play an important role in multiple ophthalmic sub-specialties such as refraction, corneal disease, glaucoma, and optometry. For instance, in refractive surgery, HEIDERBERG’s ANTERION can accurately assess corneal epithelial thickness (ETM) and visual quality to guide personalized cutting solutions; and in cataract surgery, it can take advantage of corneal topography and biometry data to reduce the risk of unexpected postoperative refractive errors.

ANTERION employs SS-OCT technology with a wavelength of 1300nm, which has the characteristics of strong penetration, fast scanning speed and high imaging resolution. Coupled with eye-tracking and ray-tracing technology, it can provide accurate, efficient and comprehensive anterior segment diagnosis and treatment solutions. Moreover, multiple examinations can be completed with one single device, greatly optimizing the clinical workflow and improving the efficiency of anterior segment diagnosis and treatment.

The approval of such product has further enriched the Group's product portfolio, especially high-end surgical and diagnostic products. The Group will continue to bring more and better products and solutions to its customers and patients.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board

**Gaush Meditech Ltd**

**Mr. Gao Tieta**

*Chairman and Executive Director*

Hong Kong, March 13, 2025

*As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.*

\* *For identification purposes only*